Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 23375386)

1.

VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium.

Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L.

Neuropeptides. 2013 Apr;47(2):85-92. doi: 10.1016/j.npep.2012.12.005. Epub 2013 Feb 1.

PMID:
23375386
2.

Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.

Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I.

Eur J Pharmacol. 2011 Nov 16;670(1):186-94. doi: 10.1016/j.ejphar.2011.08.016. Epub 2011 Sep 2.

PMID:
21914446
3.

VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.

Akesson L, Ahrén B, Edgren G, Degerman E.

Endocrinology. 2005 Feb;146(2):744-50. Epub 2004 Oct 28.

PMID:
15514088
4.
5.

Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.

Ekblad E, Jongsma H, Brabet P, Bockaert J, Sundler F.

Ann N Y Acad Sci. 2000;921:137-47.

PMID:
11193817
6.

Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.

Schulz S, Röcken C, Mawrin C, Weise W, Höllt V, Schulz S.

Clin Cancer Res. 2004 Dec 15;10(24):8235-42.

7.

Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.

Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG.

Int J Mol Med. 2002 Mar;9(3):233-43.

PMID:
11836629
8.
9.

Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.

Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K.

Neuroscience. 2012 Jan 27;202:158-68. doi: 10.1016/j.neuroscience.2011.10.055. Epub 2011 Nov 7.

PMID:
22108610
10.
11.

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA.

Cancer Res. 2000 Jun 1;60(11):3105-12.

13.

Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.

García-Fernández MO, Collado B, Bodega G, Cortés J, Ruíz-Villaespesa A, Carmena MJ, Prieto JC.

Gynecol Endocrinol. 2005 Jun;20(6):327-33.

PMID:
16019382
14.

Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes.

Grimaldi M, Cavallaro S.

Eur J Neurosci. 1999 Aug;11(8):2767-72.

PMID:
10457173
15.
16.

Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.

Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC.

Cell Signal. 1999 Nov;11(11):813-9.

PMID:
10617284
19.

Heterogeneity of neuronal and smooth muscle receptors involved in the VIP- and PACAP-induced relaxations of the pig intravesical ureter.

Hernández M, Barahona MV, Recio P, Rivera L, Benedito S, Martínez AC, García-Sacristán A, Orensanz LM, Prieto D.

Br J Pharmacol. 2004 Jan;141(1):123-31. Epub 2003 Dec 8.

20.

Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor.

Miyata A, Sato K, Hino J, Tamakawa H, Matsuo H, Kangawa K.

Ann N Y Acad Sci. 1998 Dec 11;865:73-81.

PMID:
9927999
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk